Novartis' Jakavi gets Health Canada go-ahead
This article was originally published in Scrip
Novartis' JAK inhibitor Jakavi (ruxolitinib) has received approval in its second major worldwide market with Health Canada giving the drug the green light for the treatment of disease-related splenomegaly and/or associated symptoms in adults with myelofibrosis. The approval is based on results from two Phase III studies, COMFORT I and II.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.